GSK plc
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| GLAXF | MRK | GILD | PFE | SNY | 014570.KQ | |
|---|---|---|---|---|---|---|
| Market cap | 96.21B | 370.96B | 216.41B | 175.50B | 113.74B | 30.31B |
| P/E (TTM) | 16.8 | 151.9 | — | 44.0 | 23.6 | — |
| Forward P/E | 10.9 | 16.7 | 17.3 | 10.6 | 8.9 | — |
| Price/book | 3.8 | 8.9 | 16.6 | 2.1 | 1.4 | — |
| Dividend yield | 3.80% | 2.26% | 1.88% | 5.59% | 5.10% | 6.41% |
| 1-year change | +2.30% | +75.29% | +41.39% | +23.90% | −4.08% | −35.25% |
| Today | −2.68% | +3.93% | +4.19% | +2.63% | +4.72% | −0.36% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 20 min.
Latest news
All GLAXF news ›FDA Approves GSK’s Jemperli for Certain Rectal Cancer Patients
PHILADELPHIA, PA — The U.S. Food and Drug Administration has granted accelerated approval to GSK’s Jemperli as a standalone treatment for certain patients with locally advanced rectal cancer, creating an alternative to chemotherapy,…
Alfasigma claims early FDA nod for ex-GSK liver drug
The FDA has approved Alfasigma's primary biliary cholangitis (PBC) therapy linerixibat, just days after the company licensed it from GSK in a deal worth up to $690 million. The US regulator confirmed approval of IBAT inhibitor linerixibat,…
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
— Exclusive License for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (“ATTC”), which is expected to enter clinical trials in H2 2026 —— HUTCHMED webcasts today at 4:30 p.m. HKT in Chinese (Putonghua) and at…
GSK: The Gas Pedal Is Still Down, But Bumps Ahead
GSK stock remains a Buy despite Q3 misses, with Specialty Medicines growth, pipeline momentum, valuation upside, and key risks to watch. See more here. - Despite the Q3 disappointments, I maintain my Buy rating, as strong Specialty…
GSK PLC And Hansoh Pharmaceutical Group Co., Ltd. Announce Positive Phase III Results From ARTEMIS-011 Study Evaluating Risvutatug Rezetecan In China
Published on 10/26/2026 at 11:30 am EDT In ARTEMIS-011, Ris-Rez reduced the risk of disease progression or death by 67% compared with chemotherapy, after a median follow-up of 7.1 months (HR, 0.33; 95% CI, 0.20-0.55; p In the trial, safety…
Reviewing Palisade Bio (NASDAQ:PALI) and GSK (NYSE:GSK)
Posted by Mitch Edgeman on Oct 31st, 2026 Palisade Bio (NASDAQ:PALI – Get Free Report) and GSK (NYSE:GSK – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the…
Morgan Stanley raises Aviva; Jefferies cuts GSK
Published on 10/29/2026 at 06:07 am EDT (Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Monday: Bernstein raises Whitbread price target to 2,850 (2,500) pence - 'market-perform'…
GSK Shares: Analyst Sees Limited Earnings Momentum Ahead
Advertising pays for our free market news, analysis and trading tools. If you accept, we and our partners may also match and combine data from other sources, link your devices, and identify your device from its characteristics, precise…
Jefferies Downgrades GSK to Hold, Price Target is $55.90
Published on 10/29/2026 at 09:00 am EDT GSK plc: Seize the dip after Q3 Vaccines miss October 28, 2026 at 02:40 pm EDT Berenberg still a buyer of GSK, considering stock undervalued GSK: shareholders urge company to step up reinvention
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com65
- seekingalpha.com15
- stocktitan.net11
- themarketsdaily.com6
- biospace.com4
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.